Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
BioSpace
Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs' failure to improve motor function in a c
pharminent
July 1, 2026 (Last updated: July 1, 2026)
BioSpace
Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs’ failure to improve motor function in a c
